Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Tremelimumab vs Sorafenib in Advanced Hepatocellular Carcinoma
jRCT2080223793Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2018
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial in hepatocellular carcinoma (HCC) comparing Durvalumab + Tremelimumab with Sorafenib (2 arms). Started Feb 2018; status: completed.
02
Drugs
durvalumabtremelimumabsorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCT2080223793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223793.